Abstract
Fibromyalgia (FM) may be an unrecognized cause of suffering for persons with an array of medical conditions. This is especially true for illness that is characterized by pain of any nature. Once believed to be a unique diagnosis, FM is recently reported to occur concomitantly with various rheumatic diseases, and importantly adversely impacts global health status. However, there is increasing report of FM associated with other diseases that are not defined by chronic pain. This qualitative review examines the evidence for comorbid FM in illness, and where available the effect of FM on the primary disease. Other than for musculoskeletal disorders, the published literature reporting an association of FM with illness is limited with scanty reports for some neurological, gastrointestinal, mental health and other overlapping pain conditions. Comorbid FM adversely affects both health status and outcome for rheumatic diseases, but with limited study in other diseases. When unrecognized, comorbid FM may be mistaken as poor control of the primary disease, leading to incorrect treatment decisions. FM may be a neglected condition that pervades many conditions and may contribute to the burden of illness. Physicians should be alert to the possibility of comorbid FM, and symptoms of FM should be specifically addressed. Significance: Comorbid fibromyalgia (FM) in other medical conditions is largely unrecognized. When reported as accompanying rheumatic diseases, FM adversely affects global health status. With limited reports of comorbid FM with other conditions, neglect to diagnose comorbid FM may misdirect treatments.
Background and objective
The syndrome fibromyalgia (FM) is characterized by chronic widespread body pain with associated symptoms of fatigue, sleep disturbance and other somatic symptoms (Wolfe et al., 2010 (Wolfe et al., , 2016 but may also be a comorbid condition with various rheumatologic diseases, with adverse effect on global well-being (Sarzi-Puttini et al., 2015) .
The understanding of FM has evolved from the early concept of a solely pain condition, to the acceptance of symptoms beyond pain, as exemplified by the most recent 2016 criteria (Wolfe et al., 2016) . The burden of illness for FM is considerable, with both personal suffering, more wide-reaching psychosocial implications of compromised function at home and work, and considerable direct and indirect costs (Schaefer et al., 2016) . Ghavidel-Parsa and colleagues have recently coined the phrase 'the iceberg nature of fibromyalgia burden', emphasizing the invisible aspects of FM that insidiously permeate the daily lives of patients (Ghavidel-Parsa et al., 2015) . Although initially recognized as a unique condition, with population prevalence rates of 2-4%, there is recent appreciation that this total burden of illness will be compounded when FM coexists with some other condition, as recognized for various rheumatic diseases. Comorbid FM is associated with a less favourable health status, more severe symptoms and impaired function (Sarzi-Puttini et al., 2015) . However, the association of FM with other nonrheumatic diseases is less commonly recognized. As physicians practicing in the specialities of rheumatology and internal medicine, as well as pain medicine, the authors have the clinical impression that FM concomitant with other illnesses is being seen more commonly in clinical practice. This clinical perception has therefore prompted an evaluation of the literature in this regard and the following report.
Beyond the compounding effect of impact on overall quality of life, recognition of FM as a comorbid condition is important for two additional reasons. Firstly, although the primary medical condition carries major weight for treatment choices, associated FM may require specifically directed management. Secondly and in contrast, unrecognized FM may be misinterpreted as poor control of the primary disease with management misdirected towards the underlying disease, rather than focus towards managing FM.
In this qualitative review, we have examined the reported prevalence of FM as a concomitant condition with various medical conditions including rheumatic and nonrheumatic diseases, and where reported, have noted the effect of comorbid FM on the underlying primary disease. We will further discuss the meaning of FM and highlight the consequences for clinical care.
Database
We present a qualitative review of the literature based on a selective search of the literature in MED-LINE published from 1990 to September 2017 using the following MeSH (Medical subject Heading) terms: 'fibromyalgia', 'chronic widespread pain', 'comorbid' matched with 'rheumatic disease', 'neurologic disease', 'gastrointestinal disease', 'medical condition', 'endocrine disease', 'metabolic disease', 'mental health disorder', 'psychological illness', 'psychiatric disease', and 'mental health'. From the references of relevant articles, we accessed additional literature relevant to the topic. In view of the paucity of articles, various medical conditions, the absence of any systematic review, and different methods of identification of FM, we have provided a narrative review as well as author opinion, rather than a systematic review.
Results
FM has been identified using various criteria over the years. The current most commonly used diagnostic criteria for FM are the 2011 revision of the American College of Rheumatology (ACR) preliminary diagnostic criteria for FM published in 2010, which allow for patient completed questionnaires and therefore use in a survey setting (Wolfe et al., 2010 (Wolfe et al., , 2011a . Prior to 2010, FM was identified using the ACR 1990 criteria, which required physician examination of tender points (Wolfe et al., 1990 ). There are six broad categories of conditions that can associate with FM: (1) rheumatic diseases, both inflammatory and noninflammatory, (2) neurological diseases and (3) internal diseases other than rheumatic diseases, (4) other functional pain syndromes (chronic overlapping conditions), (5) mental disorders, (6) sleep disorders, see Table 1 .
Rheumatic diseases
Comorbid FM is reported to occur in 20 to 30% of patients with various rheumatic conditions. In a North American databank cohort of over 6000 patients, FM was identified in 21% with rheumatoid arthritis (RA), 37% with systemic lupus erythematosis and 17% with osteoarthritis (OA) (Wolfe et al., 2011a) . Similar rates of 19-22% for 172 RA patients and 24-30% for 122 scleroderma patients were reported for French patients (Perrot et al., 2017) . In a Spanish study of 437 patients with primary Sjogren's syndrome, FM was identified in 14.6% (Torrente-Segarra et al., 2017) . FM occurs in between 12% and 20% of patients with spondyloarthritis (SpA) and 10-14% with psoriatic arthritis (PsA) (Haliloglu et al., 2014; Salaffi et al., 2014; Fan et al., 2017) .
Comorbid FM is also reported to occur in patients with noninflammatory musculoskeletal conditions. Ten per cent of 238 persons with osteoarthritis (OA) were reported with comorbid FM (Haliloglu et al., 2014) . This figure is even higher for chronic spinal pain, with 25% of 655 persons with chronic low back pain reported with FM in a primary care setting, and the number increasing to over 40% for patients with a primary spine diagnosis in an academic pain service (Brummett et al., 2013a; Viniol et al., 2013) . Similarly, between one in three to five older adults with chronic low back pain are reported to have an associated FM (Fatemi et al., 2015) . FM has also been reported as a comorbid condition in between 23% and 41% of patients with chronic disabling occupational musculoskeletal disorders evaluated in a US rehabilitation programme (Howard et al., 2010) . Generalized joint laxity can be associated with chronic body pain. Between 2% and over 50% of persons from various populations are recognized as been hypermobile, and about 3% of hypermobile persons experience chronic body pain, termed hypermobility syndrome (Scheper et al., 2015) . It is, however, not entirely clear that there is a true distinction between hypermobility syndrome and FM in a person who is hypermobile. When the effect of comorbid FM on the underlying disease has been examined, the burden of suffering is greater for all rheumatic diseases described to date (Haliloglu et al., 2014; Sarzi-Puttini et al., 2015; Fan et al., 2017) . For example, for RA and scleroderma, FM was associated with higher pain intensity and greater disability (Perrot et al., 2017) . Patients with Sjogren's syndrome and FM had more constitutional symptoms (although not further specified), fatigue and arthralgia compared to those without FM (Torrente-Segarra et al., 2017) . Pragmatically, patients with comorbid FM are usually excluded from clinical trials of disease-modifying agents in RA as it is believed that comorbid FM may influence study outcome. Outcome for RA disease response to the biologic agent certolizumab pegol was adversely affected by the presence of a concomitant somatization comorbidity phenotype representing FM, even although the research protocol had specifically excluded patients with FM at study entry (Curtis et al., 2017) . Similarly, comorbid FM had a negative effect on the response of patients with axial SpA treated with tumour necrosis factor blockers (Molto et al., 2018) . Surgical outcomes may also be adversely impacted by comorbid FM, as has been described for patients undergoing joint replacement surgery for OA (Brummett et al., 2015) . A higher FM survey score was independently predictive of less improvement in pain and was also independently predictive of change in overall pain and patient global impression of change (Brummett et al., 2015) . Children undergoing spine fusion surgery for idiopathic scoliosis and identified as having a behavioural pain vulnerable profile had poorer and possibly long-lasting pain outcomes (Voepel-Lewis et al., 2017).
Neurological diseases
The four neurological conditions that have been reported to associate with pain or FM are multiple sclerosis (MS), postpoliomyelitis syndrome, neuropathic pain and Parkinson's disease (PD). However, there is no study that has assessed the outcome of the underlying disease in the presence of FM. Both the incidence and the prevalence of FM appear to be slightly higher in MS compared to the general population (Marrie et al., 2015) . In a large Canadian population study, the prevalence of FM in persons with MS versus a matched population cohort was 6.82% versus 3.04% (95% CI: 5.91-7.72), whereas the incidence of FM was 44% higher in the MS cohort compared to the population cohort after adjustment for age, sex and year (Marrie et al., 2012) . FM was also more prevalent in females than males at the time of MS diagnosis with a female-tomale ratio 2.10 (95% CI: 1.55-2.86) (Marrie et al., 2016) .
Postpolio syndrome occurs in an estimated 50% of persons following poliomyelitis infection, with musculoskeletal symptoms, including pain, reported more commonly in those with postpolio syndrome. FM, identified by 1990 American College of Rheumatology criteria using a tender point count, was identified in 10.5% of 105 postpoliomyelitis patients presenting to a specialized postpolio clinic, with a further 10% identified as borderline FM (Trojan and Cashman, 1995) . In this latter study, those identified with FM were more likely to be female and complain of fatigue, but other features of postpolio condition did not differ between those with or without FM (Trojan and Cashman, 1995) .
Neuropathic pain is mostly recognized as a burning quality pain felt in limbs distally, but can also be widespread. FM was identified in a third of patients with hereditary neuropathy with liability to pressure palsy (Yilmaz et al., 2015) .
Although the presence of FM has not been specifically addressed in PD, up to two-thirds of patients experience some pain, but with earlier studies reporting that pain was not significantly different from controls (Rana et al., 2013) . Moderate severity musculoskeletal pain in PD associated with sleep disturbance, depressed mood and compromised activities of daily living (Fu et al., 2017) . The stiffness that can occur in the early stages of PD may be interpreted as pain, and could have features of a diffuse pain syndrome (Toda and Harada, 2010) . Moreover, the comorbid symptoms of PD such as fatigue, sleep, mood and cognitive disturbances have similarities with FM.
Previous FM has recently been reported to be a predictor of complex regional pain syndrome (CRPS) following distal radius fracture (Lipman et al., 2017) . A medicare database of over 800,000 patients with distal radius fracture identified an association of FM and CRPS with an odds ratio of 2.0. Furthermore, female gender, surgery or manipulation and anxiety were positively associated with this complication.
Gastrointestinal disease
Prevalence of FM in gastrointestinal disease has mostly been reported for coeliac disease and irritable bowel syndrome (IBS). Coeliac disease or the spectrum of noncoeliac gluten sensitivity, the latter currently hotly debated, have many somatic symptoms, including myalgia and arthralgia that mimic FM (Aziz et al., 2016) . Chronic widespread pain or FM by ACR 1990 criteria was present in 14.9% and 11.4%, respectively, of 114 coeliac patients attending an Italian coeliac clinic (Tovoli et al., 2013) . Musculoskeletal pain resembling FM has been reported in 31% of a cohort of 468 Italian patients suspected of having noncoeliac gluten sensitivity (Volta et al., 2014) . We did not identify any study on the prevalence or effect on clinical outcome of FM in noncoeliac gluten sensitivity.
The prevalence rate of FM in consecutive IBS patients in gastroenterology departments in Israel, Pakistan and the United Kingdom ranged from 17% to 32%, and was 30% in a Norwegian populationbased study (Sperber et al., 1999; Vandvik et al., 2006; Erbasan et al., 2017) . One study demonstrated a negative impact of FM on physical functioning in IBS and one study on healthcare consultation because of IBS symptoms (Sperber et al., 1999; Vandvik et al., 2006) .
There are discrepant reports for prevalence of FM in inflammatory bowel disease, with a study from Norway reporting FM in 18 of 521 patients (3.5%), similar to the population prevalence, whereas an Israeli study reported FM according to the ACR 1990 criteria in 30% of 113 patients, and more commonly in those with Crohn's disease (Buskila et al., 1999; Palm et al., 2001) . No studies on the impact of FM on clinical outcome in IBD were found.
Overlapping chronic pain conditions
Overlap of FM and various chronic pain syndromes is prevalent. Previously identified as central sensitivity or functional somatic syndromes, the U.S. Congress and National Institutes of Health has recommended the term Chronic Overlapping Pain Conditions (COPCs) (Chronic Pain Research Alliance). These pain conditions involve many organ systems and include vulvodynia, temporomandibular disorders, myalgic encephalomyelitis/chronic fatigue syndrome, irritable bowel syndrome, interstitial cystitis/painful bladder syndrome, endometriosis, chronic tension-type headache, chronic migraine headache and chronic low back pain. Prevalence rates for FM in these various conditions range from 20% to 65% (Sarzi-Puttini et al., 2012 ).
An US study found a prevalence of FM according to the ACR 2010 criteria in 28% of patients with chronic migraine and in 67% in patients with chronic tension headache (Cho et al., 2017) . Comobrid FM had a negative impact on migraine-associated, but not on tension headache associated symptoms. However, there are contradictory findings. A Brazilian study did not find differences in the prevalence of FM in women with endometriosis (Nunes et al., 2014 ) and a Taiwanese study found the same in women with painful bladder syndrome (Fan et al., 2014; Nunes et al., 2014) .
Endocrine disease and obesity
Although various untreated endocrine diseases may have generalized pain and fatigue as symptoms, once the underlying disease is effectively treated, it can be expected that the pain symptoms resolve. Endocrine conditions that can present with pain include various thyroid disorders, hyperparathyroidism, and acromegaly (Lugo et al., 2012; Tagoe et al., 2013; Boone et al., 2017) . The presence of thyroid autoimmunity has a negative impact on FM severity (Bazzichi et al., 2007) . In a Turkish study, 62% of patients with Hashimoto thyroiditis met the ACR 2010 criteria of FM (Haliloglu et al., 2017) .
Obesity is a risk factor for the development of FM (Dias et al., 2017) . FM was identified in 45% of 98 morbidly obese patients according to the 2011 ACR criteria. In this study, conducted at a bariatric surgery clinic, depression was the only comorbid condition that was more prevalent in those with FM (24.14% vs. 5.45%), leading the authors to suggest that depression may be a risk factor for the development of FM in this patient group (Dias et al., 2017) .
Other internal diseases
Cardiac failure is not commonly associated with chronic pain. Therefore, the report that FM occurred in 23% of persons with cardiac failure is of particular interest (Gist et al., 2017) . In this study of 57 patients, 63% male and mean age 70 years, Gist and coauthors assessed FM using the 2011 ACR criteria, and overall health function was assessed with the short-form (SF-36). Those with FM had poorer overall well-being, but comparable severity of cardiac failure. In 300 patients with primary immunodeficiency (Immunoglobulin subclass IgG and common variable immunodeficiency), the prevalence of FM according to the ACR 1990 or 2010 criteria was 19.6%. There were significant interactions of chronic fatigue, interstitial cystitis and Sj€ ogren's syndrome with FM (Barton et al., 2017) .
Mental health and sleep disorders
Studies have mostly addressed the prevalence of mental health disorders in patients with FM, with less study of the converse. In a German study, 38% of patients diagnosed with depressive disorder in two psychiatric departments met criteria for FM (Hauser et al., 2010) , using a self-report questionnaire composed of a regional pain scale and a fatigue score (Katz et al., 2006) . In an Israel study, 26% of female and 2% of male patients with major depression met the ACR 1990 criteria of FM (Vishne et al., 2008) . In an Israeli single-centre study, the prevalence of FM in patients with PTSD was 21%, and in another study with only male patients was 10% (Amir et al., 1997; Arnson et al., 2007) . Sleep disturbance is an important symptom for patients with FM; however, FM was identified in only 2.7% of patients attending for a primary sleep disorder, with pain report associated with physical activity (Donald et al., 1996) . There are conflicting results of an association of sleep apnoea with FM. One Brazilian study reported a prevalence of 22% and one French study of 3.4% (Plantamura et al., 1995; Germanowicz et al., 2006) .
Discussion
We have examined and synthesized the current literature pertaining to the concomitant association of FM with other medical conditions. Comorbid FM has most commonly been reported for inflammatory and noninflammatory rheumatic diseases, with estimates of at least one in five persons having an associated FM. FM is less commonly recognized as a comorbid condition in other illnesses that may have a pain component, with only limited reports of FM for mostly some neurological and gastrointestinal conditions. However, comorbid FM has been reported in some mental disorders and heart failure whose defining symptoms are not pain. Importantly, comorbid FM associates with an overall less favourable health status for those with rheumatic diseases, including rheumatoid arthritis, inflammatory spondyloarthritis, psoriatic arthritis, and less favourable outcome following surgery for osteoarthritis, or response to interventions for back pain (Brummett et al., 2013a (Brummett et al., ,b, 2015 Curtis et al., 2017) . FM has also been shown to have a negative impact on nonrheumatic conditions including cardiac failure, IBS and PTSD. As FM has mostly been a rheumatology focussed condition, it is possible that nonrheumatologists have not been attuned to comorbid FM, or may still be unfamiliar with the evolving concept of FM.
Towards an understanding of the concept of comorbid fibromyalgia
There are three scenarios that should be taken into consideration when FM associates with some other medical condition. Firstly, FM may have predated the disease, but it is unknown whether pre-existing FM specifically affects disease expression. However, to borrow from the legal tradition, a 'thin-skull' diathesis does suggest a particular fragility that may influence the impact of a new disease. The effect may simply be additive of the individual components of each disease, or may even be an exaggerated effect that compounds the overall burden of suffering.
Secondly, the individual may possess a pain prone phenotype with any pain able to initiate sensitization resulting in amplification of pain intensity and location. For example, persons with OA localized pain exhibit hyperalgesia even at sites distant from the OA site, indicating widespread multimodality changes in the nociceptive system (Moss et al., 2016) . 'Remaining pain' in RA, reported to occur for about 60% of patients with well-controlled inflammatory disease, may also reflect this pain prone phenotype (Altawil et al., 2016) . Although reports of remaining pain have not specifically invoked FM, the hypothesized mechanism of peripheral nerve sensitization represents a pathogenesis similar to FM.
Finally, factors other than a specific pain generator may be influential in comorbid FM. Symptoms such as poor mood and sleep, depression, fatigue or reduced physical activity as well as biopsychosocial factors may be operative. Other than the severity of disease, future FM in RA patients was predicted by social disadvantage, psychological distress, and somatic comorbidity (Wolfe et al., 2011b) .
Chronic widespread pain is the defining clinical feature of FM. Irrespective of the final understanding of the pathophysiological mechanism for FM, chronic widespread pain impacts well-being, function, and has societal implications for health care costs. Although central sensitization is regarded to be the pathophysiological hallmark of FM (Clauw, 2014) , features of central sensitization have been demonstrated in many other chronic pain conditions (Arendt-Nielsen et al., 2018) . In the absence of a simple clinical test to measure central sensitization, a high score for the American College of Rheumatology survey criteria for FM, otherwise identified as a scale of polysymptomatic distress, has been used as a surrogate measure by some authors (Clauw, 2014; Nicol et al., 2016) .
In addition, the association between FM and some mental disorders such as PTSD and chronic overlapping pain conditions such as chronic tension headache and IBS can be explained by symptom overlap, for example by sleep and concentration problems for PTSD and abdominal pain and fatigue for IBS (Hauser et al., 2013) .
Even if the concept of central sensitization is accepted by the majority of pain physicians, some authors question that there is an overarching central sensitization mechanism common to all so-called central hypersensitivity syndromes (Walitt et al., 2016) . Nonbelievers in central sensitization may conceptualise comorbid FM or high scores in the polysymptomatic distress scale, termed by some 'fibromyalgianess', as a measure of high somatic and psychological symptom burden which might be explained by psychological mechanisms or somatization (Wolfe, 2009; Curtis et al., 2017) . We found that comorbid fibromyalgia/fibromyalgianess affected health outcomes in some medical conditions. 'Comorbid fibromyalgia' or high fibromyalgianess scores are a measure of total symptom burden. Total somatic symptom score provided a predictor of health status and healthcare use over and above the effects of anxiety, depression and general medical diseases in nine population-based studies with ca 30 000 participants (Tomenson et al., 2013) .
Implications for clinical care
Implications for clinical care for comorbid FM are bidirectional. Unrecognized FM will result in failure to adequately address the key symptoms of pain, fatigue and unrefreshed sleep. In contrast, symptoms of FM may artificially inflate measurements of disease activity; especially those that incorporate global assessment of health status or pain, and mislead medical management to focus on the underlying disease rather than the FM. Patient's pain perception is an important driver of global health status for many conditions. Pain rating exerted the greatest influence on Disease Activity Score in 28 joints (DAS 28) in a study of over 500 outpatients with RA (Leeb et al., 2007) . Similarly, DAS 28 overestimated objective RA severity in RA patients with associated FM compared to those without FM (Coury et al., 2009) . Pain has been shown to be the strongest determinant of patient global assessment in a study of 260 patients with active RA, indicating that factors other than disease activity influence the final score and such overreporting may adversely affect treatment decisions (Ward et al., 2017) . These FM driven inflated disease scores may lead to inappropriate treatment decisions such as changes in treatments of the underlying disease or inappropriate dosage escalations of current treatments. Therefore, a treatment approach that addresses FM symptoms rather than adjusting disease-specific treatments is required. In consideration of surgical treatments, underlying FM should alert the healthcare team to be more vigilant in the post-operative care of patients to limit potential adverse outcomes.
Recognition of fibromyalgia
The assessment of FM in the setting of some other disease has evolved over the years. Initially the diagnosis of FM was made using the original 1990 American College of Rheumatology (ACR) criteria that comprised pain and tender point examination, whereas more recent reports utilize the updated ACR criteria that have eliminated the tender point examination, incorporated symptoms beyond pain, and comprise a questionnaire that can be completed by a patient and applicable to surveys (Wolfe et al., 1990 (Wolfe et al., , 2011a . The questionnaire allows for the calculation of a scale of composite of suffering and identified as the polysymptomatic distress scale (PSD).
In the clinical setting, FM may be recognized by a report of chronic widespread pain of at least 3 months duration, in association with symptoms that can include sleep and mood disturbance, fatigue, cognitive difficulties and various somatic symptoms. As a simple clinical first step, completion of a pain diagram could alert the clinician to a more widespread pain complaint, even for those presenting with a major symptom of regional pain. Although criteria for the diagnosis of FM were initially developed to classify patients for research purposes, application of current criteria, interpreted in the clinical context, may be used to guide a clinical diagnosis (Wolfe et al., 2016) .
Rather than a distinct disease, FM should be conceptualised as the end of a continuum of somatic [including pain sites] and psychological symptom burden (distress). Even within FM, different grades of severity can be differentiated, with fluctuation in status supporting the concept of a continuum of suffering measured as polysymptomatic distress introduced by Wolfe (Wolfe et al., 2015) . Irrespective of whether a patient meets one of the diagnostic criteria for FM, the PSD can be applied to every patient with a chronic painful condition (Wolfe et al., 2015) . High scores can be regarded as a marker of central sensitization or of high somatic and psychological symptom burden (so-called somatization) (Hauser et al., 2009 ).
Limitations
There are a number of limitations to this qualitative analysis and opinion piece that should be highlighted. To date, there have been no systematic reviews addressing comorbid FM with any medical condition. Therefore, the present study is based on assessment of a variety of individual and heterogeneous studies. Over the years various authors have used differing diagnostic criteria to assign a diagnosis of FM. This is understandable as the diagnostic criteria for FM have changed quite considerably since the formal recognition of FM with the ACR 1990 diagnostic criteria; however, these different criteria represent a lack of uniformity. Secondly, the various patient cohorts described differ in many aspects, with some authors focussing on a specific disease, whereas others reported prevalence rates for a variety of diseases within a specific study. This is particularly true for those with rheumatic disorders. The setting for patient cohorts also differs. Finally, numbers of patients included in studies are variable and range from under 100 patients to less than 1000 patients, often without clear description of patient ascertainment. In the light of these limitations we are unable to provide a robust analysis of the data, but rather have developed a qualitative report indicating that there is a clinical signal that requires further dedicated study. However, if different settings and different diagnostic criteria result in similar findings (e.g. for IBS), this might be a signal of the robustness of the results.
Summary
Comorbid FM is likely an unrecognized condition for many medical conditions that have a pain component. Most commonly reported to associate with rheumatic disorders, there are only limited reports of comorbid FM with other conditions, e.g. neurological, mental health and gastrointestinal conditions. The impact of comorbid FM on global health is considerable for rheumatic diseases, but other than for cardiac failure, has not yet been adequately assessed for other conditions. It is, however, reasonable to predict that comorbid FM will have similar negative impact on other conditions, if measured.
In that there is now a growing body of the literature describing FM in the setting of rheumatic conditions, but much less regarding nonrheumatic disease, we hope that this qualitative review and the opinions expressed by the authors will open a window to the appreciation that comorbid FM may be an unrecognized component of suffering for an array of medical conditions. We urge that it is timely to alert other medical disciplines to formally examine for both the prevalence and the impact of FM or polysymptomatic distress in medical conditions associated with pain and fatigue. It is hoped that the concept of polysymptomatic distress will permeate medical care and that disciplines other than rheumatologists and pain physicians will begin to actively explore this possible association in clinical care. FM/ fibromyalgianess may be an ignored symptom for patients diagnosed with an array of medical conditions and may represent a hidden and neglected cause of suffering.
